Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
[PubMed - indexed for MEDLINE]
2.

Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?

Rüegg C, Dormond O, Foletti A.

Endothelium. 2002;9(3):151-60. Review.

PMID:
12380640
[PubMed - indexed for MEDLINE]
3.

Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.

Rüegg C, Dormond O, Mariotti A.

Biochim Biophys Acta. 2004 Mar 4;1654(1):51-67. Review.

PMID:
14984767
[PubMed - indexed for MEDLINE]
Free Article
4.

Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.

Cai W, Chen X.

Anticancer Agents Med Chem. 2006 Sep;6(5):407-28. Review.

PMID:
17017851
[PubMed - indexed for MEDLINE]
5.

Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.

Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM.

Cancer Res. 2003 May 1;63(9):2079-87.

PMID:
12727823
[PubMed - indexed for MEDLINE]
Free Article
6.

Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.

Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, Fukuchi Y, Takahashi K.

Lung Cancer. 2007 Sep;57(3):302-10. Epub 2007 May 4.

PMID:
17482311
[PubMed - indexed for MEDLINE]
7.

alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment.

Hodivala-Dilke K.

Curr Opin Cell Biol. 2008 Oct;20(5):514-9. doi: 10.1016/j.ceb.2008.06.007. Epub 2008 Aug 6. Review.

PMID:
18638550
[PubMed - indexed for MEDLINE]
8.

Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.

McQuade P, Knight LC, Welch MJ.

Bioconjug Chem. 2004 Sep-Oct;15(5):988-96.

PMID:
15366951
[PubMed - indexed for MEDLINE]
9.

A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis.

Lim EH, Danthi N, Bednarski M, Li KC.

Nanomedicine. 2005 Jun;1(2):110-4. Review. No abstract available.

PMID:
17292065
[PubMed - indexed for MEDLINE]
10.

Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.

Shin IS, Jang BS, Danthi SN, Xie J, Yu S, Le N, Maeng JS, Hwang IS, Li KC, Carrasquillo JA, Paik CH.

Bioconjug Chem. 2007 May-Jun;18(3):821-8. Epub 2007 Mar 22.

PMID:
17375899
[PubMed - indexed for MEDLINE]
11.

Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3).

McQuade P, KnIght LC.

Q J Nucl Med. 2003 Sep;47(3):209-20. Review.

PMID:
12897712
[PubMed - indexed for MEDLINE]
Free Article
12.

The alpha v integrin antagonists as novel anticancer agents: an update.

Kerr JS, Slee AM, Mousa SA.

Expert Opin Investig Drugs. 2002 Dec;11(12):1765-74. Review.

PMID:
12457436
[PubMed - indexed for MEDLINE]
13.

Non peptidic alphavbeta3 antagonists: recent developments.

Cacciari B, Spalluto G.

Curr Med Chem. 2005;12(1):51-70. Review.

PMID:
15638730
[PubMed - indexed for MEDLINE]
14.

A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.

Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1215-27.

PMID:
15001266
[PubMed - indexed for MEDLINE]
15.

Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment.

Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):143-58. Review.

PMID:
18221059
[PubMed - indexed for MEDLINE]
16.

Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M.

Clin Exp Metastasis. 2003;20(5):413-20.

PMID:
14524530
[PubMed - indexed for MEDLINE]
17.

New targeted probes for radioimaging of angiogenesis.

Stollman TH, Ruers TJ, Oyen WJ, Boerman OC.

Methods. 2009 Jun;48(2):188-92. doi: 10.1016/j.ymeth.2009.03.006. Epub 2009 Mar 24. Review.

PMID:
19318127
[PubMed - indexed for MEDLINE]
18.

Angiogenesis inhibitors. Drug selectivity and target specificity.

Kesisis G, Broxterman H, Giaccone G.

Curr Pharm Des. 2007;13(27):2795-809. Review.

PMID:
17897024
[PubMed - indexed for MEDLINE]
19.

Multimodality imaging of tumor integrin alphavbeta3 expression.

Chen X.

Mini Rev Med Chem. 2006 Feb;6(2):227-34. Review.

PMID:
16472190
[PubMed - indexed for MEDLINE]
20.

Radionuclide imaging of tumor angiogenesis.

Dijkgraaf I, Boerman OC.

Cancer Biother Radiopharm. 2009 Dec;24(6):637-47. doi: 10.1089/cbr.2009.0694. Review.

PMID:
20025543
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk